News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website


Musella Foundation Grant Award to Tocagen - Interim Progress Report

Al's Comment:

 Just a quick update to show how YOUR donations are being used!  

Posted on: 12/16/2012

Musella Foundation Grant Award to Tocagen - Interim Progress Report


The Musella Foundation recently awarded Tocagen Inc. ( a grant to support the clinical investigation of Toca 511 & Toca FC in patients with recurrent Grade 3 glioma brain cancer (  Since awarding this grant, we are pleased to report that Tocagen has enrolled three Grade 3 patients that have been supported, in part, by this grant.  It is innovations like Toca 511 & Toca FC that we believe may make a difference in the lives of these patients.


Toca 511 & Toca FC is designed to kill cancer cells from within while leaving healthy cells unharmed. Tocagen is enrolling patients across the U.S. in two multicenter, open-label investigational clinical trials. These studies are evaluating patients with recurrent high-grade glioma, who have had prior surgery and chemoradiation. In one study, Toca 511 is delivered directly to the tumor under real-time MRI guidance while in the second protocol, Toca 511 is injected into the walls of the resection cavity immediately following removal of the tumor.  More details can be found on by searching for Tocagen under the “Find a Treatment” tab.



Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557